|
Items in cart [0] |
Questions? Call 888-624-8373 |
HARDBACK + PDF HARDBACK PDF BOOK PDF CHAPTERS Free Resources |
||||||||||||||||
|
||||||||||||||||
The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. Hippocrates, 125 Historical estimates of costs, 179 HIV/AIDS combining drugs for treatment, 4 costs for treatment, 9 external support for control, 75 funding sources for treatment, 105 global market for drugs, 86 informed buying of drugs, 119–120 malaria and, 156–157 price discrimination for drugs, 65 HMS. See Hyperreactive malarial splenomegaly Ho Chi Minh, 133 Holleykin, 307–308 Homer, 125 Hospital-based evidence. See Health care facilities, evidence Host genetics, 146–147 House siting and construction, 210 Household expenditures on prevention, 184, 193 expenditures on treatment, 184–185, 193 living standards, 182–183 Humanitarian rationale, 80 Hyperlactatemia, 149 Hyperreactive malarial splenomegaly (HMS), 158 Hypoglycemia, 149, 150, 154, 269 I IDA. See World Bank, International Development Association IFPMA. See International Federation of Pharmaceutical Manufacturers Associations I.G. Farben, 131 Illegal drug flows, 41–42 Illiad, The (Homer), 125 IMCI. See Integrated management of childhood illness Imidazolinedione derivatives, 309 In vitro testing, 278 In vivo testing, 273, 274, 276–279 India Bsph toxin, 211 Calcutta, 129 chloroquine resistance, 276 cinchona plantations, 130 control programs, 234 DDT use, 198 mosquito nets, 203 pharmaceuticals from, 36 R&D, 308 user fees, 100 Indoor residential spraying. See Insecticide spraying, indoor residential Infants, intermittent preventive therapy. See Intermittent preventive therapy, infants INNs. See International Nonproprietary Names Insecticide spraying indoor residential (IRS), 11, 144, 199, 206–207 Insecticides, 200–202 Insecticide-treated nets (ITNs). See also Bednets Abuja Summit target, 50 history of, 202–203 individual and community effects of, 203–209 social marketing of, 56 Institut Pasteur, 224 Institute of Lausanne, 224 Institute of Medicine (IOM) Committee on the Economics of Antimalarial Drugs, 19, 51, 113 Insurance programs, 100 Integrated management of childhood illness (IMCI), 56, 77, 220, 324 Intellectual property issues, 117 Intermittent preventive therapy (IPT) children (IPTc), 219 pregnant women (IPTp), 56, 77, 218–219 SP and, 22 strategy, 324 TEHIP study, 56–60
|
|
|||||||||||||||
